The impact of willingness-to-pay threshold on price reduction recommendations for oncology drugs: a review of assessments conducted by the Canadian Agency for Drugs and Technologies in Health

• প্রধান লেখক: Chakrapani Balijepalli (লেখক), Lakshmi Gullapalli (লেখক), Juhi Joshy (লেখক), Nigel SB Rawson (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Becaris Publishing Limited, 2024-04-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

Since late 2020, the Canadian Agency of Drugs and Technologies in Health (CADTH) has been using a threshold of $50,000 (CAD) per quality-adjusted life-year (QALY) for both oncology and non-oncology drugs. When used for oncology products, this threshold is hypothesized to have a higher impact on the...